SCHEMBL5363560

SCHEMBL5363560

CN(C)c1ccc2cccc(N3CCN(C(=O)OC(C)(C)C)CC3)c2n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.45
SKP1 P63208 2/20 0.45
SKP2 Q13309 2/20 0.45
BACE1 P56817 4/20 0.43
MAP4K4 O95819 1/20 0.43
SMARCA2 P51531 1/20 0.43
SMARCA4 P51532 1/20 0.43
PBRM1 Q86U86 1/20 0.43
ACHE P22303 2/20 0.43
PTPN11 Q06124 1/20 0.42
PARP1 P09874 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
GPR119 Q8TDV5 2/20 0.42
TLR9 Q9NR96 1/20 0.42
POLB P06746 1/20 0.41
GBA1 P04062 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4009513 0.85 GRM5 (0.47) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL5365178 0.83 CKS1B (0.46) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL5371139 0.82 ACHE (0.47) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL14551197 0.82 CKS1B (0.45) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL1048457 0.81 POLB (0.55) CKS1BSKP1SKP2MAP4K4SMARCA2
SCHEMBL7521558 0.77 CKS1B (0.54) CKS1BSKP1SKP2MAP4K4ACHE
SCHEMBL2848519 0.77 HRH1 (0.43) CKS1BSKP1SKP2BACE1MAP4K4
SCHEMBL4558301 0.75 BACE1 (0.59) CKS1BSKP1SKP2BACE1SMARCA2
SCHEMBL5335208 0.75 GPR119 (0.50) CKS1BSKP1SKP2SMARCA2SMARCA4
SCHEMBL520960 0.74 CKS1B (0.49) CKS1BSKP1SKP2BACE1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 CKS1B 1801/4885SKP1 725/4885SKP2 3195/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 CKS1B 1801/4885SKP1 725/4885SKP2 3195/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 CKS1B 1801/4885SKP1 725/4885SKP2 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.